New Study Finds No Tie Between Aluminum-Adjuvanted Vaccines and Autoimmune, Allergic, and Neurodevelopmental Conditions

HHS secretary Robert F. Kennedy Jr. asked a vaccine advisory group to scrutinize vaccines containing aluminum despite the growing body of evidence it has no ties to conditions like autism.
July 15, 2025

A new study that took place over 24 years found that there is “no tie between exposure to aluminum-adjuvanted childhood vaccines and autoimmune, atopic or allergic, or neurodevelopmental conditions such as autism.” CIDRAP has the news.

The study comes less than a month after HHS secretary Robert F. Kennedy Jr. “reportedly asked a government vaccines advisory group to scrutinize dozens of aluminum-containing vaccines that have been in use for nearly 100 years.” Aluminum-based adjuvants “are often used in inactivated vaccines, including childhood vaccines against diphtheria, tetanus, and pertussis (Tdap), Haemophilus influenzae type b (Hib), pneumococcal conjugate vaccine (PCV), and hepatitis A and B to boost immune responses, the study authors noted.”

Researchers looked at registry data on childhood vaccinations and “aluminum content, outcomes, and potential confounding factors in the first 2 years of life among more than 1.2 million children born in Denmark from 1997 to 2018.” Only 1.2% of the children received no aluminum-adjuvanted vaccines before age 2. The team looked for “vaccine-related events involving 50 chronic conditions” during follow-up.

The researchers found “no association between cumulative aluminum exposure in vaccines in the first 2 years of life and increased risk of any of the 50 chronic conditions.”

About the Author

Matt MacKenzie

Associate Editor

Matt is Associate Editor for Healthcare Purchasing News.

Sign up for Healthcare Purchasing News eNewsletters